Endpoint surrogacy in oncology Phase 3 randomised controlled trials

Jianrong Zhang; Meagan R. Pilar; Xiaofei Wang; Jingxia Liu; Herbert Pang; Ross C. Brownson; Graham A. Colditz; Wenhua Liang; Jianxing He

doi:10.1038/s41416-020-0896-5

Endpoint surrogacy in oncology Phase 3 randomised controlled trials

Jianrong Zhang
, Meagan R. Pilar
, Xiaofei Wang
, Jingxia Liu
, Herbert Pang
, Ross C. Brownson
, Graham A. Colditz
, Wenhua Liang
, Jianxing He

Research output: Contribution to journal › Editorial

12 Scopus citations

Abstract

Endpoint surrogacy is an important concept in oncology trials. Using a surrogate endpoint like progression-free survival as the primary endpoint—instead of overall survival—would lead to a potential faster drug approval and therefore more cancer patients with an earlier opportunity to receive the newly approved drugs.

Original language	English
Pages (from-to)	333-334
Number of pages	2
Journal	British Journal of Cancer
Volume	123
Issue number	3
DOIs	https://doi.org/10.1038/s41416-020-0896-5
State	Published - Aug 4 2020

Access to Document

10.1038/s41416-020-0896-5

Cite this

@article{53ffc3b2d0754b23b4653c5c171ae945,

title = "Endpoint surrogacy in oncology Phase 3 randomised controlled trials",

abstract = "Endpoint surrogacy is an important concept in oncology trials. Using a surrogate endpoint like progression-free survival as the primary endpoint{\textemdash}instead of overall survival{\textemdash}would lead to a potential faster drug approval and therefore more cancer patients with an earlier opportunity to receive the newly approved drugs.",

author = "Jianrong Zhang and Pilar, \{Meagan R.\} and Xiaofei Wang and Jingxia Liu and Herbert Pang and Brownson, \{Ross C.\} and Colditz, \{Graham A.\} and Wenhua Liang and Jianxing He",

note = "Publisher Copyright: {\textcopyright} 2020, Cancer Research UK.",

year = "2020",

month = aug,

day = "4",

doi = "10.1038/s41416-020-0896-5",

language = "English",

volume = "123",

pages = "333--334",

journal = "British Journal of Cancer",

issn = "0007-0920",

number = "3",

}

TY - JOUR

T1 - Endpoint surrogacy in oncology Phase 3 randomised controlled trials

AU - Zhang, Jianrong

AU - Pilar, Meagan R.

AU - Wang, Xiaofei

AU - Liu, Jingxia

AU - Pang, Herbert

AU - Brownson, Ross C.

AU - Colditz, Graham A.

AU - Liang, Wenhua

AU - He, Jianxing

PY - 2020/8/4

Y1 - 2020/8/4

N2 - Endpoint surrogacy is an important concept in oncology trials. Using a surrogate endpoint like progression-free survival as the primary endpoint—instead of overall survival—would lead to a potential faster drug approval and therefore more cancer patients with an earlier opportunity to receive the newly approved drugs.

AB - Endpoint surrogacy is an important concept in oncology trials. Using a surrogate endpoint like progression-free survival as the primary endpoint—instead of overall survival—would lead to a potential faster drug approval and therefore more cancer patients with an earlier opportunity to receive the newly approved drugs.

UR - https://www.scopus.com/pages/publications/85085283393

U2 - 10.1038/s41416-020-0896-5

DO - 10.1038/s41416-020-0896-5

M3 - Editorial

C2 - 32451466

AN - SCOPUS:85085283393

SN - 0007-0920

VL - 123

SP - 333

EP - 334

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 3

ER -

Endpoint surrogacy in oncology Phase 3 randomised controlled trials

Abstract

Access to Document

Other files and links

Fingerprint

Cite this